INB-03

INmune Bio has partnered with Cell and Gene Therapy Catapult to establish commercial-scale manufacturing for CORDStrom, a promising therapy for recessive dystrophic epidermolysis bullosa that showed positive results in Phase 2 trials.

INmune Bio presented baseline demographics from its MINDFuL Phase II trial showing 208 patients with early Alzheimer's disease and confirmed biomarkers of inflammation, with 69.2% being APOE ε4 carriers.

INmune Bio's Natural Killer cell therapy INKmune™ demonstrates strong safety profile in Phase I trial for metastatic castration-resistant prostate cancer, enabling progression to Phase II high-dose cohort.

INmune Bio's CaRe PC trial, evaluating INKmune in metastatic castration-resistant prostate cancer (mCRPC), has expanded to the West Los Angeles VA Medical Center.

The FDA has accepted Insmed's New Drug Application for brensocatib in bronchiectasis, granting Priority Review with a PDUFA target action date of August 12, 2025.